General Renal Cancer

New Drug Beats Standard Therapy in Advanced Kidney Cancer (December 13, 2016)

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of... Continue Reading

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer (December 5, 2016)

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results... Continue Reading

Obesity Linked to Improved Survival in Kidney Cancer (September 12, 2016)

Obesity almost always increases cancer risk and worsens outcomes, but researchers led by scientists at Dana-Farber Cancer Institute report that overweight patients with advanced kidney cancer had significantly... Continue Reading

Surgery Can Lengthen Survival of Metastatic Kidney Cancer Patients Treated with Targeted Therapies, Study Finds (July 6, 2016)

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in 10 such patients undergo the procedure, according... Continue Reading

Lenvima® Approved for Kidney Cancer (May 24, 2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received... Continue Reading

Cabometyx™ Approved for Kidney Cancer (May 10, 2016)

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx™ (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients... Continue Reading

FDA Approves Opdivo for Renal Cell Carcinoma (November 25, 2015)

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600... Continue Reading

FDA Grants Breakthrough Therapy Designation to LENVIMA™ for the Potential Treatment of Metastatic Renal Cell Carcinoma (August 3, 2015)

Eisai Inc. has announced that the U.S. Food and Drug Administration (FDA) granted LENVIMA™ (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation... Continue Reading

Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival (July 29, 2015)

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase... Continue Reading

National Kidney Cancer Awareness Month on CancerConnect (March 6, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of kidney cancer educational programs for national kidney cancer awareness month. As the month of March brings kidney... Continue Reading

Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene... Continue Reading

First-Line Inlyta Active in Metastatic Kidney Cancer (December 11, 2013)

First-line therapy with Inlyta® (axitinib) demonstrated clinical activity in metastatic renal cell carcinoma, according to the results of a study published in The Lancet Oncology. Each year in the United... Continue Reading

New Treatment Options for Advanced Renal Cell Carcinoma (October 8, 2012)

The results from three phase III trials shed new light on treatment options for patients with advanced renal cell carcinoma. The studies were presented at the ESMO 2012 Congress of the European Society... Continue Reading

PD-1 Targeted Immune Therapy Shows Promising Activity (June 11, 2012)

The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase... Continue Reading

Partial Nephrectomy is Associated with Improved Survival in Early Stage Kidney Cancer (April 27, 2012)

Patients with early stage kidney cancer who had only the tumor removed experienced better survival rates than those who had the entire kidney removed, according to the results of a study published in the... Continue Reading

Tivozanib Promising for Metastatic Renal Cell Carcinoma (April 23, 2012)

Tivozanib (AV-951) was well tolerated and improved median progression-free survival (PFS) in some patients with advanced renal cell carcinoma (RCC), according to the results of a phase II study published... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing... Continue Reading

Targeted Drugs Produce Complete Responses in Some Patients with Metastatic Kidney Cancer (February 28, 2012)

Some patients with metastatic kidney cancer experience a complete response (a complete disappearance of detectable cancer) after treatment with Sutent® (sunitinib) or Nexavar® (sorafenib), but researchers... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS